Clinically relevant doses of fluoxetine and reboxetine induce changes in the TrkB content of central excitatory synapses

Neuropsychopharmacology

Volumn 31, Issue 11, 2006, Pages 2415-2423

  Wyneken, Ursula ^a   Sandoval, Mauricio ^a   Sandoval, Soledad ^a   Jorquera, Franscisco ^a   González, Ignacio ^a   Vargas, Francisco ^a   Falcon, Romina ^a   Monari, Milena ^a   Orrego, Fernando ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

BDNF; Fluoxetine; Glutamate receptors; Postsynaptic density; Reboxetine; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; FLUOXETINE; GLUTAMATE RECEPTOR 1; METABOTROPIC GLUTAMATE RECEPTOR 1ALPHA; METABOTROPIC RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROTROPHIN RECEPTOR; PROLIFT; PROTEIN P75; REBOXETINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ENDOCYTOSIS; ENDOSOME; HIPPOCAMPUS; IMMUNOBLOTTING; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SYNAPSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOTTING, WESTERN; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; GLUTAMIC ACID; IMMUNOPRECIPITATION; MALE; MORPHOLINES; PHOSPHOTYROSINE; RAB5 GTP-BINDING PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TRKB; SUBCELLULAR FRACTIONS; SYNAPSES; TIME FACTORS;

EID: 33750223155     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301052     Document Type: Article

References (72)

1. Aghajanian GK (1995). Electrophysiology of serotonin receptor subtypes and signal transduction pathways. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, pp 451-460 ( www.acnp.org/g4/GN 401000043/Ch043.html ).
2. Alvarez JC, Bothua D, Collignon I, Advenier C, Spreux-Varoquaux O (1998). Determination of fluoxetine and its metabolite norfluoxetine in serum and brain areas using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 707: 175-180.
3. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D et al (1997). Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 154: 963-969.
4. Andrade R, Nicoll RA (1987). Pharmacologically distinct actions of serotonin on single pyramidal neurons of the rat hippocampus recorded in vitro. J Physiol Lond 394: 99-124.
5. + current in mammalian neurons. Proc Natl Acad Sci USA 92: 6635-6639.
6. Araneda R, Andrade R (1991). 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40: 399-412.
7. Beck SG (1992). 5-Hydroxytryptamine increases excitability of CA1 hippocampal cells. Synapse 10: 334-340.
8. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP (2000). Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23: 428-438.
9. Caccia S, Bizzi A, Coltro G, Fracasso C, Frittoli E, Mennini T et al (1992). Anoretic activity of fluoxetine and norfluoxetine in rats: relationship between brain concentrations and in-vitro potencies on monoaminergic mechanisms. J Pharm Pharmacol 44: 250-254.
10. Caccia S, Confalonieri S, Bergami A, Fracasso C, Anelli M, Garattini S (1997). Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: a comparison with fluoxetine. Pharmacol Biochem Behav 57: 851-856.
11. Castrén E (2004). Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol 4: 58-64.
12. Cellerino A, Maffei L, Domenici L (1996). The distribution of brain - derived neurotrophic factor and its receptor trkB in parvalbumin - containing neurons of the rat visual cortex. Eur J Neurosci 8: 1190-1197.
13. Chao MV (2003). Neurotrophins and their receptors: a convergence point for many signalling pathways. Nature Rev Neurosci 4: 299-309.
14. Charlier C, Pinto E, Ansseau M, Plomteux G (2000). Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 15: 453-459.
15. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatr 50: 260-265.
16. Contreras CM, Rodriguez-Landa JF, Gutierrez-Garcia AG, Bernal-Morales B (2001). The lowest effective dose of fluoxetine in the forced swim test significantly affects the firing rate of lateral septal nucleus neurones in the rat. J Psychopharmacol 15: 231-236.
17. Coppell AL, Pei Q, Zetterström TSC (2003). Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44: 903-910.
18. Coyle JT, Duman RS (2003). Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 157-160.
19. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
20. Demchyshyn LL, Pristupa ZB, Sugamori KS, Barker EL, Blakely RD, Wolfgang WJ et al (1994). Cloning, expression, and localization of a chloride- facilitated, cocaine-sensitive serotonin transporter from Drosophila melanogaster. Proc Natl Acad Sci USA 91: 5158-5162.
21. Duman R, Malberg J, Nakagawa S, D'Sa C (2000). Neuronal plasticity and survival in mood disorders. Biol Psychiaty 48: 732-739.
22. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatr 54: 597-606.
23. Duman RS, Vaidya VA (1998). Molecular and cellular actions of chronic electroconvulsive seizures. J ECT 14: 181-193.
24. Ernfors P, Bramham CR (2003). The coupling of a trkB tyrosine residue to LTP. Trends in Neurosci 26: 171-173.
25. Foehring RC, van Brederode JF, Kinney GA, Spain WJ (2002). Serotonergic modulation of supragranular neurons in rat sensorimotor cortex. J Neurosci 22: 8238-8250.
26. Fuller RW (1994). Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55: 163-167.
27. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S (2003). [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47: 123-133.
28. 7 receptors. J Physiol Lond 541: 453-465.
29. Grimes ML, Miettinen HM (2003). Receptor tyrosine kinase and G-protein coupled receptor signaling and sorting within endosomes. J Neurochem 84: 905-918.
30. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y et al (2005). Relationship between brain serotonin transporter binding, plasma concentration and behavioral effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144: 695-702.
31. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde Y-A (1990). Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 9: 2459-2464.
32. Holladay JW, Dewey MJ, Yoo SD (1998). Kinetic interaction between fluoxetine and imipramine as a function of elevated serum alpha-1-acid glycoprotein levels. J Pharm Pharmacol. 50: 419-424.
33. Howe CL, Valletta JS, Rusnak AS, Mobley WC (2001). NGF signaling from clathrin - coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. Neuron 32: 801-814.
34. Huang EJ, Reichardt LF (2003). Trk receptors: roles in neuronal signal transduction. Ann Rev Biochem 72: 609-642.
35. Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004). Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 486: 277-285.
36. Ji Y, Pang PT, Feng L, Lu B (2005). Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci 8: 164-172.
37. Kennedy MB (2000). Signal-processing machines at the postsynaptic density. Science 290: 750-754.
38. Larkman PM, Kelly JS (1992). Ionic mechanisms mediating 5-hydroxytryptamine-and noradrenaline-evoked depolarization of adult rat facial motoneurones. J Physiol London 456: 473-490.
39. Lee J, Duan W, Mattson MP (2002). Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82: 1367-1375.
40. Li KW, Hornshaw MP, Van Der Schors RC, Watson R, Tate S, Casetta B et al (2004). Proteomics analysis of rat brain postsynaptic density. Implications of the diverse protein functional groups for the integration of synaptic physiology. J Biol Chem 279: 987-1002.
41. Lee KH, McCormick DA (1996). Abolition of spindle oscillations by serotonin and norepinephrine in the ferret lateral geniculate and perigeniculate nuclei in vitro. Neuron 17: 309-321.
42. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X et al (2005). Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 13: 1254-1262.
43. Madison DV, Nicoll RA (1986a). Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurons, in vitro. J Physiol 372: 221-244.
44. Madison DV, Nicoll RA (1986b). Cyclic adenosine 3′, 5′-monophosphate mediates beta-receptor actions of noradrenaline in rat hippocampal pyramidal cells. J Physiol London 372: 245-259.
45. McCormick DA, Pape HC, Williamson A (1991). Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog Brain Res 88: 293-305.
46. Meyer-Franke A, Wilkinson GA, Kruttgen A, Hu M, Munro E, Hanson MG et al (1998). Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS Neurons. Neuron 21: 681-693.
47. Nemeroff CB, Krishnan KR, Blazer DG, Knight DL, Benjamin D, Meyerson LR (1990). Elevated plasma concentrations of alpha 1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients. Arch Gen Psychiatry 47: 337-340.
48. Nemeroff CB, Owens MJ (2002). Treatment of mood disorders. Nature Neurosci suppl 5: 1068-1070.
49. Nestler EJ, Barrot M, DiLeone RJ, Eish AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25.
50. Nibuya M, Nestler EJ, Duman RS (1996). Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16: 2365-2372.
51. Perrone JA, Chabla JM, Hallas BH, Horowitz JM, Torres G (2004). Weight loss dynamics during combined fluoxetine and olanzapine treatment. BMC Pharmacol 4: 27.
52. Rocamora N, Welker E, Pascual M, Soriano E (1996). Upregulation of BDNF mRNA expression in the barrel cortex of adult mice after sensory stimulation. J Neurosci 16: 4411-4419.
53. Russo-Neustadt A, Beard RC, Cotman CW (1999). Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacol 21: 679-682.
54. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ (2004). Hippocampal Brain-Derived Neurotrophic Factor Expression Following Treatment with Reboxetine, Citalopram, and Physical Exercise. Neuropsychopharmacology 29: 2189-2199.
55. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al (2003). Activation of the TrkB neurotrophin receptors is induced by antidepressant drugs and is required for antidrepressant-induced behavioral effects. J Neurosci 23: 349-357.
56. Shirayama Y (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261.
57. Smalla KH, Matthies H, Langnase K, Shabir S, Bockers TM, Wyneken U et al (2000). The synaptic glycoprotein neuroplastin is involved in long-term potentiation at hippocampal CA1 synapses. Proc Natl Acad Sci USA 97: 4327-4332.
58. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85. Erratum in: Anal Biochem 1987;163:279.
59. Soto D, Pancetti F, Marengo JJ, Sandoval M, Sandoval R, Orrego F et al (2004). Protein kinase CK2 in postsynaptic densities: phosphorylation of PSD-95/SAP90 and NMDA receptor regulation. Biochem Biophys Res Commun 322: 542-550.
60. Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR (2002). Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Am J Psychiatry 159: 755-760.
61. Torres GE, Chaput Y, Andrade R (1995). Cyclic AMP and protein kinase A mediate 5-hydroxytryptamine type 4 receptor regulation of calcium-activated potassium current in adult hippocampal neurons. Mol Pharmacol 47: 191-197.
62. Wallén P, Buchanan JT, Grillner S, Hill RH, Christenson J, Hökfelt T (1989). Effects of 5-Hydroxytryptamine on the after hyper polarization, spike frequency regulation, and oscillatory membrane properties in lamprey spinal cord neurons. J Neurophysiol 61: 759-768.
63. Watson FL, Heerssen HM, Moheban DB, Lin MZ, Sauvageot CM, Bhattacharyya A et al (1999). Rapid nuclear responses to target - derived neurotrophins require retrograde transport of ligand - receptor complex. J Neurosci 19: 7889-7900.
64. Weissman M, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu H-G et al (1996). Cross-national epidemiology of major depression and bipolar disorder. J Am Med Assoc 276: 293-299.
65. Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N et al (2002). Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 22: 568-575.
66. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP (2000). Reboxetine: a pharmacologically potent, selective and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
67. Wyneken U, Marengo JJ, Villanueva S, Soto D, Sandoval R, Gundelfinger ED et al (2003). Epilepsy-induced changes in signaling systems of human and rat postsynaptic densities. Epilepsia 44: 243-246.
68. Wyneken U, Smalla K-H, Marengo JJ, Soto D, De la Cerda A, Tischmeyer W et al (2001). Kainate-induced seizures alter protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic densities. Neuroscience 102: 65-74.
69. York RD, Molliver DC, Grewal SS, Stenberg PE, McCleskey EW, Stork PJS (2000). Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via Ras and Rap1. Mol Cell Biol 20: 8069-8083.
70. Zarate Jr CA, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J et al (2003). Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci 1003: 273-291.
71. Zetterstrom TS, Pei Q, Grahame-Smith DG (1998). Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res 57: 106-110.
72. Ziff EB (1997). Enlightening the postsynaptic density. Neuron 19: 1163-1174.